A phase III trial of FMX103 (minocycline) for the treatment of moderate-to-severe papulopustular rosacea.

Trial Profile

A phase III trial of FMX103 (minocycline) for the treatment of moderate-to-severe papulopustular rosacea.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs Minocycline (Primary)
  • Indications Rosacea
  • Focus Therapeutic Use
  • Acronyms FX2016-12
  • Most Recent Events

    • 27 Jun 2018 According to a Foamix media release, patient enrolment in this study has been completed and last patient has been dosed. Top-line results are expected in the fourth quarter of this year.
    • 27 Jun 2018 Status changed from recruiting to active, no longer recruiting, according to the Foamix media release.
    • 12 Jun 2017 Status changed from not yet recruiting to recruiting according to a Foamix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top